$6.00
−4.15%Oct 8, 2026, 11:32 UTC
Clearmind Medicine announced that a patent application covering 3-MMC-based treatment of dyskinesia, including compositions combining 3-MMC with palmitoylethanolamide, was published in Japan.
Source:Oct 7, 2026, 12:40 UTC
Clearmind Medicine Inc. submitted recommendations to the U.S. Food and Drug Administration on regulatory pathways for psychedelic therapies and non-hallucinogenic neuroplastogens for alcohol use disorder.
Source:Sep 23, 2026, 12:15 UTC
NeuroThera Labs highlighted the expansion of its U.S. patent portfolio through its ongoing collaboration with Clearmind Medicine, covering proprietary combinations of NeuroThera's PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications.
Sep 23, 2026, 11:57 UTC
Clearmind Medicine announced the publication of three U.S. patent applications covering LSD, ketamine and ibogaine combinations for potential therapeutic uses in mental health and substance use disorders.
Source:Sep 17, 2026, 13:58 UTC
Clearmind Medicine's Chief of Global Impact, Mary-Elizabeth Gifford, testified at a U.S. Food and Drug Administration hearing in Washington, D.C. on the potential future therapeutic use of psychedelic drugs, addressing patient access.
Source:Sep 17, 2026, 11:42 UTC
Clearmind Medicine delivered a briefing to the FDA after being invited to a psychedelic hearing in Washington, D.C., where its Chief of Global Impact Mary-Elizabeth Gifford spoke on patient access and shared insights from the company's clinical trial at Yale and Johns Hopkins.
Source:Sep 11, 2026, 12:00 UTC
Clearmind Medicine Inc. announced the enrollment of the first patients with Alcohol Use Disorder in its ongoing clinical trial evaluating CMND-100, its proprietary psychedelic-based treatment candidate for AUD.
Source:Sep 8, 2026, 11:42 UTC
Clearmind Medicine received Yale University IRB approval to initiate patient recruitment for Parts B and C of its Phase I/II clinical trial of CMND-100, following positive safety results.
Source:Sep 4, 2026, 11:32 UTC
CLEARMIND MEDICINE signed a definitive agreement to acquire a 51% stake in a wireless charging company focused on automated parking and robotaxis.
Sep 1, 2026, 11:37 UTC
Clearmind Medicine initiated Phase IIa of its Phase I/IIa clinical trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled at two medical centers in Israel.
Source:Aug 24, 2026, 12:03 UTC
Clearmind Medicine announced the U.S. publication of a patent application covering MDMA-N-acylethanolamines for PTSD treatment, expanding IP from its collaboration with Neurothera Labs Inc.
Aug 13, 2026, 18:05 UTC
Clearmind Medicine's independent Data and Safety Monitoring Board approved advancing its Phase 1/2 clinical trial for alcohol addiction treatment on Thursday.
Source:Aug 6, 2026, 12:00 UTC
Clearmind Medicine announced that its independent Data and Safety Monitoring Board unanimously approved advancing its Phase I/II clinical trial of CMND-100 in Alcohol Use Disorder patients to parts B and C.
Source:Aug 3, 2026, 12:02 UTC
Clearmind Medicine Inc. announced on August 3, 2026 that it signed a non-binding Letter of Intent to acquire a 51% majority stake in an unnamed company specializing in EV wireless charging solutions for automated parking systems.
Source: